effect overlay
activetrials
Stroke
Stroke
EMU: EMVision Validation Study

Multi-Centre, Prospective, Consecutive, Paired Diagnosis, Diagnostic Performance Study of the EMVision emu™ Brain Scanner in the Detection of Intracranial Haemorrhage in Suspected Stroke Patients (The “EMU” Study)

HREC: 2025.052
Principal Investigator: Dr Anna Balabanski
Coordinator contact:
Funding: Commercial
Stroke
Stroke
ALNylam

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA)

HREC: 2024.264
Principal Investigator: A/Prof Nawaf Yassi
Coordinator contact: David Jackson
Funding: Commercial
Epilepsy
Epilepsy
BHV7000 Refractory Focal Onset Epilepsy 303

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy

HREC: 2024.145
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact:
Funding: Commercial
Dementia
Dementia
TRAILBLAZER 5

Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease: I5T-MC-AACO

HREC: 2024.122
Principal Investigator: Prof Amy Brodtmann
Coordinator contact: Sophie Robinson
Funding: Commercial
Dementia
Dementia
TARGET TAU

A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)

HREC: 2024.121
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Sophie Robinson
Funding: Commercial